CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
Weak investor sentiment for cheap ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,016.10 | 57.40 | 0.64% |
| CAC 40 | 8,192.43 | 130.12 | 1.61% |
| DAX 40 | 24,771.42 | 369.72 | 1.52% |
| Dow JONES (US) | 49,298.25 | 356.35 | 0.73% |
| FTSE 100 | 10,390.48 | 171.37 | 1.68% |
| HKSE | 26,213.78 | 315.17 | 1.22% |
| NASDAQ | 25,326.13 | 258.33 | 1.03% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,145.19 | 109.49 | 0.84% |
| S&P 500 | 7,259.22 | 58.47 | 0.81% |
| S&P/ASX 200 | 8,793.60 | 58.60 | 0.67% |
| SSE Composite Index | 4,160.17 | 48.01 | 1.17% |